MANALAPAN, NJ, Sept. 13, 2017 -- RxS LLC (“RxS”), a privately held company providing multi-channel sample management solutions to pharmaceutical and biotech companies, announced today its move to a new location to accommodate the company’s continued growth and success. Remaining in Manalapan, NJ, RxS is now operating at:
|
|||||||||||||
195 Route 9 S., Suite 208
Manalapan, NJ 07726
Pharmaceutical and biotech companies are often burdened by the regulations surrounding sample management, and that’s where RxS comes in. RxS offers customizable solutions for multi-channel sample management to companies of all sizes, ensuring compliance, state-of-the-art reporting, and outstanding customer service. “We are a service organization enabled by technology,” says Mark Jara, Principal, Managing Director. “Because RxS has proven to be a valuable business partner for so many companies, RxS has moved to a new location to accommodate our growth and success.”
RxS has maintained organizational growth year after year, including sales, clients, employees, and services. Over the past two years they had a surge in new clients and business expansion. The new office space will support RxS’s promising trajectory as well as creating a high tech collaborative environment to optimize customer service and enhance technical development.
The move, however, is just one of several new developments for RxS. Concurrent to this action, the company is continuing the growth of its European footprint. In addition, RxS has entered the planning phase for a proposed satellite location in southeastern Florida slated to open by mid-2018.
RxS has become a leading provider of multi-channel sample management solutions. RxS’s growing presence and continued success is credited to its leadership team that collectively has more than 75 years of pharmaceutical expertise, along with the employees’ immense knowledge and understanding of the pharma and biotech industries. Beyond that, RxS has been built on technology and is committed to providing superior customer service.
By having technology at its core, RxS can provide offerings that ensure Prescription Drug Marketing Act compliance and also supply valuable reporting and analytics data. Customers can access up-to-date reporting and analytics data 24 hours a day, seven days a week, a feature that makes proactive monitoring possible. This results in customers having the tools to advance marketing reach and optimizing sample effectiveness.
Customer service is paramount to the team at RxS. In the client-supplier relationship, the company views itself as a business partner rather than simply a vendor as account representatives learn each client’s needs and provide client centric solutions designed to drive success. RxS has found this to be a most effective approach, as the solutions they provide clients are transparent and value-centric in terms of pricing.
RxS’s success is a direct reflection of the value it has provided and continues to provide its customers. For example, by applying industry experiences and a consultative approach, RxS was able to provide a small-sized client with guidance on best practices, lead-in project management and technical integrations during their first prescription representative product sampling launch. The result was an overwhelming success that relieved the client of startup complexities while achieving compliance through a solid forward thinking framework, on time and on budget.
The value RxS provides customers extends also to more established pharmaceutical and biotech companies. For instance, a client needed to transition from having multiple vendors to a consolidated solution, so RxS provided such a solution and also strategic value during the transition. RxS achieved this by working with numerous internal and external stakeholders to identify scope and requirements. The outcome was a solution that met the deadline and budget and also had a positive impact throughout the company, from headquarters to customers.
RxS works with companies of all sizes and provides truly client centric solutions that meet each client’s needs. To learn more about RxS offerings please visit rxsinfo.com. To schedule a visit to their new headquarters, please email [email protected].
RxS LLC, a privately held company in Manalapan, New Jersey, is the leading provider of multi-channel sample management solutions for pharmaceutical and biotech companies. Supported by more than 75 years of combined pharmaceutical leadership experience, RxS has been partnering with pharmaceutical and biotech companies since its founding in 2011 to provide regulatory compliance in order to lessen the administrative burden of the Prescription Drug Marketing Act. RxS offerings go beyond regulatory compliance, providing solutions to increase marketing and sample effectiveness. Driven by technology, RxS offers a suite of proprietary services and software solutions to ensure regulatory compliance and maximize analytics data.
# # #
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3fa66210-a0be-4307-b66f-3fc3e92e4361
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2c04c05e-388c-4cc6-a173-cef94eb39845
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/47e38a37-f9b1-41d3-883a-9ba03c746912
Drew Deeter RxS 2153483890 [email protected]


Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 



